Baidu
map

CELL:SARS-CoV-2刺突糖蛋白的结构、功能和抗原性

2020-03-11 MedSci原创 MedSci原创

研究人员确定了SARS-CoV-2 刺突外域三聚体的低温电子显微镜结构,为设计疫苗和病毒侵入抑制剂提供了蓝图。

最近几个月,SARS-CoV-2的出现已经导致了> 90000人感染,> 3000人死亡。冠状病毒(Coronavirus)刺突糖蛋白促进其进入细胞,是抗体的主要靶标。

最近,研究人员发现,SARS-CoV-2 刺突利用ACE2进入细胞,而SARS-CoV-2 刺突和SARS-CoV 刺突的受体结合域与人类ACE2具有类似的亲和力,这与SARS-CoV-2在人类中的有效传播有关。

研究人员发现,SARS-CoV-2糖蛋白在S1/S2亚基之间的边界处有一个呋喃裂解位点,该位点在生物发生过程中被处理,将该病毒与SARS-CoV和与SARS相关的CoVs区分开。

研究人员确定了SARS-CoV-2 刺突外域三聚体的低温电子显微镜结构,为设计疫苗和病毒侵入抑制剂提供了蓝图。

最后,研究人员证明了SARS-CoV小鼠多克隆抗体能够有效地抑制SARS-CoV-2介导的细胞进入,这表明免疫后可以诱导针对保守的S表位的交叉中和抗体。

 

原始出处:

Alexandra C. Walls et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. CELL, 2020; DOI: https://doi.org/10.1016/j.cell.2020.02.058

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1871600, encodeId=7f7818e160099, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 14 20:22:49 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961893, encodeId=c1911961893ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 19 16:22:49 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937901, encodeId=3c6d193e9017f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Dec 02 04:22:49 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321162, encodeId=57da132116249, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623368, encodeId=194b162336859, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627255, encodeId=9451162e25542, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1871600, encodeId=7f7818e160099, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 14 20:22:49 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961893, encodeId=c1911961893ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 19 16:22:49 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937901, encodeId=3c6d193e9017f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Dec 02 04:22:49 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321162, encodeId=57da132116249, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623368, encodeId=194b162336859, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627255, encodeId=9451162e25542, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
    2020-08-19 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1871600, encodeId=7f7818e160099, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 14 20:22:49 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961893, encodeId=c1911961893ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 19 16:22:49 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937901, encodeId=3c6d193e9017f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Dec 02 04:22:49 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321162, encodeId=57da132116249, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623368, encodeId=194b162336859, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627255, encodeId=9451162e25542, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
    2020-12-02 hukaixun
  4. [GetPortalCommentsPageByObjectIdResponse(id=1871600, encodeId=7f7818e160099, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 14 20:22:49 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961893, encodeId=c1911961893ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 19 16:22:49 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937901, encodeId=3c6d193e9017f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Dec 02 04:22:49 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321162, encodeId=57da132116249, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623368, encodeId=194b162336859, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627255, encodeId=9451162e25542, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1871600, encodeId=7f7818e160099, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 14 20:22:49 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961893, encodeId=c1911961893ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 19 16:22:49 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937901, encodeId=3c6d193e9017f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Dec 02 04:22:49 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321162, encodeId=57da132116249, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623368, encodeId=194b162336859, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627255, encodeId=9451162e25542, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1871600, encodeId=7f7818e160099, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 14 20:22:49 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961893, encodeId=c1911961893ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 19 16:22:49 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937901, encodeId=3c6d193e9017f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Dec 02 04:22:49 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321162, encodeId=57da132116249, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623368, encodeId=194b162336859, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627255, encodeId=9451162e25542, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Mar 13 07:22:49 CST 2020, time=2020-03-13, status=1, ipAttribution=)]

相关资讯

bioRxiv:“谈变色变”?新冠病毒变异真实过程

导言:前日,《国家科学评论》杂志发表文章引起热议,文章表明新冠病毒已经演化出两个亚型,其中L型的传染能力更强,各大媒体竞相报道,引起了部分群众的恐慌。事实上突变在冠状病毒这类RNA病毒中并不罕见。我们不应对文章过度解读。那么新冠病毒进化途径到底如何?

如果不隔离,人类会死亡多少?世界将会变成怎样?

2019年底,新冠肺炎,如暴风骤雨,突袭中国,让中国人老老实实的待在家里,度过了历史上最长的一个假期。掐指一算,笔者已经在家中闭关了四十来天。这场疫情,让中国8万多人感染,死亡接近3***。2月29日,比尔盖茨发表文章指出,新冠肺炎,可能时百年不遇的大流行病。此次新冠病毒的传播力很强,平均每个感染者会传染 2~3 人,形成指数级增长,并且已有确切证据表明,它可以通过轻症甚至无症状的患者传播,这意

流行病防范创新联盟发出呼吁,还有20亿美元的资金缺口可能会阻碍新冠病毒COVID-19疫苗的开发

流行病防范创新联盟(CEPI)上周五发出呼吁以寻求20亿美元的资金,来支持研发COVID-19新型冠状病毒的疫苗。

3月2日新型冠状病毒肺炎简报

截至3月1日24时新型冠状病毒肺炎疫情最新情况,25省区市新增新冠肺炎确诊病例为03月1日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例202例,新增死亡病例42例(湖北42例),新增疑似病例141例。当日新增治愈出院病例2837例,解除医学观察的密切接触者8154人,重症病例减少255例。截至3月1日24时,据31个省(自治区、直辖市)和新疆生产建设兵团报告,现有确

36岁患者出院后猝死!是新冠导致的病毒性心肌炎吗?

2020年3月4日报道了武汉硚口区一例新冠肺炎出院后,康复隔离期“猝死”的案例。

Baidu
map
Baidu
map
Baidu
map